Targeting the mitochondrial electron transport chain complexes for the induction of apoptosis and cancer treatment

Current Pharmaceutical Biotechnology

Volumn 14, Issue 3, 2013, Pages 377-389

  Rohlena, Jakub ^a   Dong, Lan Feng ^b   Neuzil, Jiri ^a,b  

^a INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer; Electron transport chain; Mitochondria; Oxidative stress

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3,3' DIINDOLYLMETHANE; ADAPHOSTIN; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; ANTIMYCIN A1; BENZYL ISOTHIOCYANATE; BUTYLATED HYDROXYANISOLE; DEGUELIN; DOXORUBICIN; FENRETINIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; OLIGOMYCIN; OXIDOREDUCTASE; PHENETHYL ISOTHIOCYANATE; PORPHYRIN DERIVATIVE; PROTEIN KINASE B; RESVERATROL; RHODAMINE 123; ROTENONE; SPHINGOMYELIN PHOSPHODIESTERASE; SUPEROXIDE; TAMOXIFEN; THENOYLTRIFLUOROACETONE; TROGLITAZONE; UNINDEXED DRUG; XANTHOHUMOL;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PH; CITRIC ACID CYCLE; GLYCOLYSIS; HUMAN; LUNG CARCINOMA; MACROMOLECULE; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RESPIRATORY CHAIN;

ANIMALS; APOPTOSIS; ELECTRON TRANSPORT; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; HUMANS; MITOCHONDRIA; NEOPLASMS;

EID: 84875284814     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011314030011     Document Type: Article

References (187)

1. Chari, R. V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res., 2008, 41, 98-107.
2. Sawyers, C. Targeted cancer therapy. Nature, 2004, 432, 294-297.
3. Druker, B. J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med., 2002, 8, S14-18.
4. Check Hayden, E. Cancer complexity slows quest for cure. Nature, 2008, 455, 148.
5. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321, 1807-1812.
6. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008, 321, 1801-1806.
7. Ellis, L. M.; Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer, 2008, 8, 579-591.
8. Scheffler, I. Mitochondria, Second Edition, John Wiley & Sons, Inc.: Hoboken, New Jersey, USA, 2008.
9. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324, 1029-1033.
10. Frezza, C.; Gottlieb, E. Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol., 2009, 19, 4-11.
11. Busk, M.; Horsman, M. R.; Kristjansen, P. E.; van der Kogel, A. J.; Bussink, J.; Overgaard, J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int. J. Cancer, 2008, 122, 2726-2734.
12. Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Saavedra, E. Energy metabolism in tumor cells. FEBS J., 2007, 274, 1393-1418.
13. Cuezva, J. M.; Sanchez-Arago, M.; Sala, S.; Blanco-Rivero, A.; Ortega, A. D. A message emerging from development: the repression of mitochondrial beta-F1-ATPase expression in cancer. J. Bioenerg. Biomembr., 2007, 39, 259-265.
14. Gough, D. J.; Corlett, A.; Schlessinger, K.; Wegrzyn, J.; Larner, A. C.; Levy, D. E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science, 2009, 324, 1713-1716.
15. Baracca, A.; Chiaradonna, F.; Sgarbi, G.; Solaini, G.; Alberghina, L.; Lenaz, G. Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim. Biophys., Acta, 2010, 1797, 314-323.
16. Modica-Napolitano, J. S.; Aprille, J. R. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res., 1987, 47, 4361-4365.
17. Davis, S.; Weiss, M. J.; Wong, J. R.; Lampidis, T. J.; Chen, L. B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J. Biol. Chem., 1985, 260, 13844-13850.
18. Summerhayes, I. C.; Lampidis, T. J.; Bernal, S. D.; Nadakavukaren, J. J.; Nadakavukaren, K. K.; Shepherd, E. L.; Chen, L. B. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc. Natl. Acad. Sci. USA, 1982, 79, 5292-5296.
19. Huttemann, M.; Lee, I.; Pecinova, A.; Pecina, P.; Przyklenk, K.; Doan, J. W. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J. Bioenerg. Biomembr., 2008, 40, 445-456.
20. Konstantinov, A. A.; Peskin, A. V.; Popova, E.; Khomutov, G. B.; Ruuge, E. K. Superoxide generation by the respiratory chain of tumor mitochondria. Biochim. Biophys. Acta, 1987, 894, 1-10.
21. Rottenberg, H.; Covian, R.; Trumpower, B. L. Membrane potential greatly enhances superoxide generation by the cytochrome bc1 complex reconstituted into phospholipid vesicles. J. Biol. Chem., 2009, 284, 19203-19210.
22. Kadenbach, B.; Ramzan, R.; Wen, L.; Vogt, S. New extension of the Mitchell Theory for oxidative phosphorylation in mitochondria of living organisms. Biochim. Biophys. Acta, 2010, 1800, 205-212.
23. Garrido, C.; Galluzzi, L.; Brunet, M.; Puig, P. E.; Didelot, C.; Kroemer, G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ., 2006, 13, 1423-1433.
24. Galluzzi, L.; Morselli, E.; Kepp, O.; Vitale, I.; Rigoni, A.; Vacchelli, E.; Michaud, M.; Zischka, H.; Castedo, M.; Kroemer, G. Mitochondrial gateways to cancer. Mol. Aspects Med., 2010, 31, 1-20.
25. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol., 2008, 18, 165-173.
26. Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene, 2006, 25, 4812-4830.
27. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov., 2010, 010, 9, 447-464.
28. Wang, F.; Ogasawara, M. A.; Huang, P. Small mitochondriatargeting molecules as anti-cancer agents. Mol. Aspects Med., 2010, 31, 75-92.
29. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria as targets for cancer chemotherapy. Semin. Cancer Biol., 2009, 19, 57-66.
30. Ralph, S. J.; Neuzil, J. Mitochondria as targets for cancer therapy. Mol. Nutr. Food Res., 2009, 53, 9-28.
31. Saraste, M. Oxidative phosphorylation at the fin de siecle. Science, 1999, 283, 1488-1493.
32. Adam-Vizi, V.; Chinopoulos, C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci., 2006, 27, 639-645.
33. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J., 2009, 417, 1-13.
34. Fruehauf, J. P.; Meyskens, F. L. Jr. Reactive oxygen species: a breath of life or death?, Clin. Cancer Res., 2007, 13, 789-794.
35. Madesh, M.; Hajnoczky, G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J. Cell Biol., 2001, 155, 1003-1015.
36. Kwong, J. Q.; Henning, M. S.; Starkov, A. A.; Manfredi, G. The mitochondrial respiratory chain is a modulator of apoptosis. J. Cell Biol., 2007, 179, 1163-1177.
37. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 2009, 8, 579-591.
38. Efremov, R. G.; Baradaran, R.; Sazanov, L. A. The architecture of respiratory complex I. Nature, 2010, 465, 441-445.
39. Berrisford, J. M.; Sazanov, L. A. Structural basis for the mechanism of respiratory complex I. J. Biol. Chem., 2009, 284, 29773-29783.
40. Fato, R.; Bergamini, C.; Leoni, S.; Strocchi, P.; Lenaz, G. Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem. Res., 2008, 33, 2487-2501.
41. Grivennikova, V. G.; Vinogradov, A. D. Generation of superoxide by the mitochondrial Complex I. Biochim. Biophys. Acta, 2006, 1757, 553-561.
42. Kudin, A. P.; Bimpong-Buta, N. Y.; Vielhaber, S.; Elger, C. E.; Kunz, W. S. Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem., 2004, 279, 4127-4135.
43. Kussmaul, L.; Hirst, J. The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc. Natl. Acad. Sci. USA, 2006, 103, 7607-7612.
44. Lambert, A. J.; Brand, M. D. Inhibitors of the quinone-binding site allow rapid superoxide production from mitochondrial NADH:ubiquinone oxidoreductase (complex I). J. Biol. Chem., 2004, 279, 39414-39420.
45. Degli Esposti, M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim. Biophys. Acta, 1998, 1364, 222-235.
46. Okun, J. G.; Lummen, P.; Brandt, U. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase). J. Biol. Chem., 1999, 274, 2625-2630.
47. Tocilescu, M. A.; Fendel, U.; Zwicker, K.; Kerscher, S.; Brandt, U. Exploring the ubiquinone binding cavity of respiratory complex I. J. Biol. Chem., 2007, 282, 29514-29520.
48. Fato, R.; Bergamini, C.; Bortolus, M.; Maniero, A. L.; Leoni, S.; Ohnishi, T.; Lenaz, G. Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species, Biochim. Biophys. Acta, 2009, 1787, 384-392.
49. Di Monte, D. A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol., 2003, 2, 531-538.
50. Drechsel, D. A.; Patel, M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic. Biol. Med., 2008, 44, 1873-1886.
51. Betarbet, R.; Sherer, T. B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A. V.; Greenamyre, J. T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 2000, 3, 1301-1306.
52. Pan-Montojo, F.; Anichtchik, O.; Dening, Y.; Knels, L.; Pursche, S.; Jung, R.; Jackson, S.; Gille, G.; Spillantini, M. G.; Reichmann, H.; Funk, R. H. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One, 2010, 5, e8762.
53. Wolvetang, E. J.; Johnson, K. L.; Krauer, K.; Ralph, S. J.; Linnane, A. W. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett., 1994, 339, 40-44.
54. Li, N.; Ragheb, K.; Lawler, G.; Sturgis, J.; Rajwa, B.; Melendez, J. A.; Robinson, J. P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem., 2003, 278, 8516-8525.
55. Pelicano, H.; Feng, L.; Zhou, Y.; Carew, J. S.; Hileman, E. O.; Plunkett, W.; Keating, M. J.; Huang, P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem., 2003, 278, 37832-37839.
56. Armstrong, J. S.; Hornung, B.; Lecane, P.; Jones, D. P.; Knox, S. J. Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW. Biochem. Biophys. Res. Commun., 2001, 289, 973-978.
57. Deng, Y. T.; Huang, H. C.; Lin, J. K. Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol. Carcinog, 2010, 49, 141-151.
58. Chun, K. H.; Kosmeder, J. W., 2nd; Sun, S.; Pezzuto, J. M.; Lotan, R.; Hong, W. K.; Lee, H. Y. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst., 2003, 95, 291-302.
59. Udeani, G. O.; Gerhauser, C.; Thomas, C. F.; Moon, R. C.; Kosmeder, J. W.; Kinghorn, A. D.; Moriarty, R. M.; Pezzuto, J. M. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res., 1997, 57, 3424-3428.
60. Oh, S. H.; Woo, J. K.; Jin, Q.; Kang, H. J.; Jeong, J. W.; Kim, K. W.; Hong, W. K.; Lee, H. Y. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int. J. Cancer, 2008, 122, 5-14.
61. Lee, H. Y.; Oh, S. H.; Woo, J. K.; Kim, W. Y.; Van Pelt, C. S.; Price, R. E.; Cody, D.; Tran, H.; Pezzuto, J. M.; Moriarty, R. M.; Hong, W. K. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J. Natl. Cancer Inst., 2005, 97, 1695-1699.
62. Dell'Eva, R.; Ambrosini, C.; Minghelli, S.; Noonan, D. M.; Albini, A.; Ferrari, N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis, 2007, 28, 404-413.
63. Nair, A. S.; Shishodia, S.; Ahn, K. S.; Kunnumakkara, A. B.; Sethi, G.; Aggarwal, B. B. Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaBregulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J. Immunol., 2006, 177, 5612-5622.
64. Hail, N., Jr.; Lotan, R. Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis, 2004, 9, 437-447.
65. Kim, W. Y.; Oh, S. H.; Woo, J. K.; Hong, W. K.; Lee, H. Y. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxiainducible factor-1alpha. Cancer Res., 2009, 69, 1624-1632.
66. Oh, S. H.; Woo, J. K.; Yazici, Y. D.; Myers, J. N.; Kim, W. Y.; Jin, Q.; Hong, S. S.; Park, H. J.; Suh, Y. G.; Kim, K. W.; Hong, W. K.; Lee, H. Y. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J. Natl. Cancer Inst., 2007, 99, 949-961.
67. Caboni, P.; Sherer, T. B.; Zhang, N.; Taylor, G.; Na, H. M.; Greenamyre, J. T.; Casida, J. E. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem. Res. Toxicol., 2004, 17, 1540-1548.
68. Moreira, P. I.; Custodio, J.; Moreno, A.; Oliveira, C. R.; Santos, M. S. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J. Biol. Chem., 2006, 281, 10143-10152.
69. Croxtall, J. D.; Emmas, C.; White, J. O.; Choudhary, Q.; Flower, R. J. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem. Pharmacol., 1994, 47, 197-202.
70. Bergan, R. C.; Reed, E.; Myers, C. E.; Headlee, D.; Brawley, O.; Cho, H. K.; Figg, W. D.; Tompkins, A.; Linehan, W. M.; Kohler, D.; Steinberg, S. M.; Blagosklonny, M. V. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res., 1999, 5, 2366-2373.
71. Osipo, C.; Gajdos, C.; Cheng, D.; Jordan, V. C. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J. Steroid Biochem. Mol. Biol., 2005, 93, 249-256.
72. Nadanaciva, S.; Bernal, A.; Aggeler, R.; Capaldi, R.; Will, Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro, 2007, 21, 902-911.
73. Yankovskaya, V.; Horsefield, R.; Tornroth, S.; Luna-Chavez, C.; Miyoshi, H.; Leger, C.; Byrne, B.; Cecchini, G.; Iwata, S. Architecture of succinate dehydrogenase and reactive oxygen species generation. Science, 2003, 299, 700-704.
74. Sun, F.; Huo, X.; Zhai, Y.; Wang, A.; Xu, J.; Su, D.; Bartlam, M.; Rao, Z. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell, 2005, 121, 1043-1057.
75. Maklashina, E.; Cecchini, G. The quinone-binding and catalytic site of complex II. Biochim. Biophys. Acta, 2010, in press.
76. Dong, L. F.; Freeman, R.; Liu, J.; Zobalova, R.; Marin-Hernandez, A.; Stantic, M.; Rohlena, J.; Valis, K.; Rodriguez-Enriquez, S.; Butcher, B.; Goodwin, J.; Brunk, U. T.; Witting, P. K.; Moreno-Sanchez, R.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res., 2009, 15, 1593-1600.
77. Dong, L. F.; Low, P.; Dyason, J. C.; Wang, X. F.; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene, 2008, 27, 4324-4335.
78. Stapelberg, M.; Gellert, N.; Swettenham, E.; Tomasetti, M.; Witting, P. K.; Procopio, A.; Neuzil, J. Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J. Biol. Chem., 2005, 280, 25369-76.
79. Wang, X. F.; Dong, L.; Zhao, Y.; Tomasetti, M.; Wu, K.; Neuzil, J. Vitamin E analogues as anticancer agents: lessons from studies with alpha-tocopheryl succinate. Mol. Nutr. Food Res., 2006, 50, 675-685.
80. Neuzil, J.; Weber, T.; Gellert, N.; Weber, C. Selective cancer cell killing by alpha-tocopheryl succinate. Br. J. Cancer, 2001, 84, 87-89.
81. Neuzil, J.; Weber, T.; Schroder, A.; Lu, M.; Ostermann, G.; Gellert, N.; Mayne, G. C.; Olejnicka, B.; Negre-Salvayre, A.; Sticha, M.; Coffey, R. J.; Weber, C. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J., 2001, 15, 403-415.
82. Tomasetti, M.; Gellert, N.; Procopio, A.; Neuzil, J. A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease? Int. J. Cancer, 2004, 109, 641-642.
83. Wang, X. F.; Birringer, M.; Dong, L. F.; Veprek, P.; Low, P.; Swettenham, E.; Stantic, M.; Yuan, L. H.; Zobalova, R.; Wu, K.; Ledvina, M.; Ralph, S. J.; Neuzil, J. A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res., 2007, 67, 3337-3344.
84. Gogvadze, V.; Norberg, E.; Orrenius, S.; Zhivotovsky, B. Involvement of Ca(2+) and ROS in alpha-tocopheryl succinate-induced mitochondrial permeabilization. Int. J. Cancer, 2010, 2010, 127, 1823-1832.
85. Weber, T.; Dalen, H.; Andera, L.; Negre-Salvayre, A.; Auge, N.; Sticha, M.; Lloret, A.; Terman, A.; Witting, P. K.; Higuchi, M.; Plasilova, M.; Zivny, J.; Gellert, N.; Weber, C.; Neuzil, J. Mitochondria play a central role in apoptosis induced by alphatocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry, 2003, 42, 4277-4291.
86. Prochazka, L.; Dong, L. F.; Valis, K.; Freeman, R.; Ralph, S. J.; Turanek, J.; Neuzil, J. Alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis, 2010, 15, 782-794.
87. Shiau, C. W.; Huang, J. W.; Wang, D. S.; Weng, J. R.; Yang, C. C.; Lin, C. H.; Li, C.; Chen, C.S. Alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of BclxL/ Bcl-2 function, J. Biol. Chem., 2006, 281, 11819-11825.
88. Neuzil, J.; Tomasetti, M.; Zhao, Y.; Dong, L. F.; Birringer, M.; Wang, X. F.; Low, P.; Wu, K.; Salvatore, B. A.; Ralph, S. J. Vitamin E analogs, a novel group of mitocans, as anticancer agents: the importance of being redox-silent, Mol. Pharmacol., 2007, 71, 1185-11199.
89. Akazawa, A.; Nishikawa, K.; Suzuki, K.; Asano, R.; Kumadaki, I.; Satoh, H.; Hagiwara, K.; Shin, S. J.; Yano, T. Induction of apoptosis in a human breast cancer cell overexpressing ErbB-2 receptor by alpha-tocopheryloxybutyric acid. Jpn. J. Pharmacol., 2002, 89, 417-421.
90. Donapaty, S.; Louis, S.; Horvath, E.; Kun, J.; Sebti, S. M.; Malafa, M. P. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Mol. Cancer Ther., 2006, 5, 309-316.
91. Shun, M. C.; Yu, W.; Park, S. K.; Sanders, B. G.; Kline, K. Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines. J. Oncol., 2010, 2010, 824-571.
92. Alleva, R.; Benassi, M. S.; Tomasetti, M.; Gellert, N.; Ponticelli, F.; Borghi, B.; Picci, P.; Neuzil, J. Alpha-tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: the role of E2F1. Biochem. Biophys. Res. Commun., 2005, 331, 1515-1521.
93. Dong, L. F.; Swettenham, E.; Eliasson, J.; Wang, X. F.; Gold, M.; Medunic, Y.; Stantic, M.; Low, P.; Prochazka, L.; Witting, P. K.; Turanek, J.; Akporiaye, E. T.; Ralph, S. J.; Neuzil, J. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res., 2007, 67, 11906-11913.
94. Neuzil, J.; Swettenham, E.; Wang, X. F.; Dong, L. F.; Stapelberg, M. alpha-Tocopheryl succinate inhibits angiogenesis by disrupting paracrine FGF2 signalling. FEBS Lett., 2007, 581, 4611-4615.
95. Neuzil, J.; Tomasetti, M.; Mellick, A. S.; Alleva, R.; Salvatore, B. A.; Birringer, M.; Fariss, M. W. Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects, Curr. Cancer Drug Targets, 2004, 4, 355-372.
96. Zhang, J. G.; Nicholls-Grzemski, F. A.; Tirmenstein, M. A.; Fariss, M. W. Vitamin E succinate protects hepatocytes against the toxic effect of reactive oxygen species generated at mitochondrial complexes I and III by alkylating agents. Chem. Biol. Interact, 2001, 138, 267-284.
97. Neuzil, J.; Massa, H. Hepatic processing determines dual activity of alpha-tocopheryl succinate: a novel paradigm for a shift in biological activity due to pro-vitamin-to-vitamin conversion. Biochem. Biophys. Res. Commun., 2005, 327, 1024-1027.
98. Mehta, A.; Shaha, C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: complex II inhibition results in increased pentamidine cytotoxicity. J. Biol. Chem., 2004, 279, 11798-11813.
99. Zhang, J. G.; Tirmenstein, M. A.; Nicholls-Grzemski, F. A.; Fariss, M. W. Mitochondrial electron transport inhibitors cause lipid peroxidation-dependent and-independent cell death: protective role of antioxidants. Arch. Biochem. Biophys., 2001, 393, 87-96.
100. Soller, M.; Drose, S.; Brandt, U.; Brune, B.; von Knethen, A. Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells, Mol Pharmacol, 2007, 71, 1535-44.
101. Graham, D. J.; Green, L.; Senior, J. R.; Nourjah, P. Troglitazoneinduced liver failure: a case study. Am. J. Med., 2003, 114, 299-306.
102. Bonsi, P.; Cuomo, D.; Martella, G.; Sciamanna, G.; Tolu, M.; Calabresi, P.; Bernardi, G.; Pisani, A. Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies. Curr. Neuropharmacol., 2006, 4, 69-75.
103. Fernandez-Gomez, F. J.; Galindo, M. F.; Gomez-Lazaro, M.; Yuste, V. J.; Comella, J. X.; Aguirre, N.; Jordan, J. Malonate induces cell death via mitochondrial potential collapse and delayed swelling through an ROS-dependent pathway. Br. J. Pharmacol., 2005, 144, 528-537.
104. Gomez-Lazaro, M.; Galindo, M. F.; Melero-Fernandez de Mera, R. M.; Fernandez-Gomez, F. J.; Concannon, C. G.; Segura, M. F.; Comella, J. X.; Prehn, J. H.; Jordan, J. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mito chondrial cytochrome c release and apoptosis in response to malonate, Mol. Pharmacol., 2007, 71, 736-743.
105. Huang, L. S.; Sun, G.; Cobessi, D.; Wang, A. C.; Shen, J. T.; Tung, E. Y.; Anderson, V. E.; Berry, E.A. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme, J. Biol. Chem., 2006, 281, 5965-5972.
106. Liot, G.; Bossy, B.; Lubitz, S.; Kushnareva, Y.; Sejbuk, N.; Bossy-Wetzel, E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA-and ROSdependent pathway. Cell Death Differ., 2009, 16, 899-909.
107. Peczkowska, M.; Cascon, A.; Prejbisz, A.; Kubaszek, A.; Cwikla, B. J.; Furmanek, M.; Erlic, Z.; Eng, C.; Januszewicz, A.; Neumann, H. P. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat. Clin. Pract. Endocrinol. Metab., 2008, 4, 111-115.
108. Schiavi, F.; Boedeker, C. C.; Bausch, B.; Peczkowska, M.; Gomez, C. F.; Strassburg, T.; Pawlu, C.; Buchta, M.; Salzmann, M.; Hoffmann, M. M.; Berlis, A.; Brink, I.; Cybulla, M.; Muresan, M.; Walter, M. A.; Forrer, F.; Valimaki, M.; Kawecki, A.; Szutkowski, Z.; Schipper, J.; Walz, M. K.; Pigny, P.; Bauters, C.; Willet-Brozick, J. E.; Baysal, B. E.; Januszewicz, A.; Eng, C.; Opocher, G.; Neumann, H. P. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA, 2005, 294, 2057-2063.
109. Iwata, S.; Lee, J. W.; Okada, K.; Lee, J. K.; Iwata, M.; Rasmussen, B.; Link, T. A.; Ramaswamy, S.; Jap, B. K. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science, 1998, 281, 64-71.
110. Xia, D.; Yu, C. A.; Kim, H.; Xia, J. Z.; Kachurin, A. M.; Zhang, L.; Yu, L.; Deisenhofer, J. Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science, 1997, 277, 60-66.
111. Drose, S.; Brandt, U. The mechanism of mitochondrial superoxide production by the cytochrome bc1 complex. J. Biol. Chem., 2008, 283, 21649-21654.
112. Chen, Q.; Vazquez, E. J.; Moghaddas, S.; Hoppel, C. L.; Lesnefsky, E. J. Production of reactive oxygen species by mitochondria: central role of complex III. J. Biol. Chem., 2003, 278, 36027-31.
113. Crofts, A. R. The cytochrome bc1 complex: function in the context of structure. Annu. Rev. Physiol., 2004, 66, 689-733.
114. Tzung, S. P.; Kim, K. M.; Basanez, G.; Giedt, C. D.; Simon, J.; Zimmerberg, J.; Zhang, K. Y.; Hockenbery, D. M. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol., 2001, 3, 183-191.
115. Le, S. B.; Hailer, M. K.; Buhrow, S.; Wang, Q.; Flatten, K.; Pediaditakis, P.; Bible, K. C.; Lewis, L. D.; Sausville, E. A.; Pang, Y. P.; Ames, M. M.; Lemasters, J. J.; Holmuhamedov, E. L.; Kaufmann, S. H. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity, J. Biol. Chem., 2007, 282, 8860-8872.
116. Chandra, J.; Hackbarth, J.; Le, S.; Loegering, D.; Bone, N.; Bruzek, L. M.; Narayanan, V. L.; Adjei, A. A.; Kay, N. E.; Tefferi, A.; Karp, J. E.; Sausville, E. A.; Kaufmann, S. H. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells, Blood, 2003, 102, 4512-4519.
117. Chandra, J.; Tracy, J.; Loegering, D.; Flatten, K.; Verstovsek, S.; Beran, M.; Gorre, M.; Estrov, Z.; Donato, N.; Talpaz, M.; Sawyers, C.; Bhalla, K.; Karp, J.; Sausville, E.; Kaufmann, S. H. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and-independent imatinib resistance, Blood, 2006, 107, 2501-2506.
118. Shanafelt, T. D.; Lee, Y. K.; Bone, N. D.; Strege, A. K.; Narayanan, V. L.; Sausville, E. A.; Geyer, S. M.; Kaufmann, S. H.; Kay, N. E. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood, 2005, 105, 2099-2106.
119. Dasmahapatra, G.; Nguyen, T. K.; Dent, P.; Grant, S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res., 2006, 30, 1263-1272.
120. Stockwin, L. H.; Bumke, M. A.; Yu, S. X.; Webb, S. P.; Collins, J. R.; Hollingshead, M. G.; Newton, D. L. Proteomic analysis identifies oxidative stress induction by adaphostin, Clin. Cancer Res., 2007, 13, 3667-3681.
121. Svingen, P. A.; Tefferi, A.; Kottke, T. J.; Kaur, G.; Narayanan, V. L.; Sausville, E. A.; Kaufmann, S. H. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin. Cancer Res., 2000, 6, 237-249.
122. Yu, C.; Rahmani, M.; Almenara, J.; Sausville, E. A.; Dent, P.; Grant, S. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK-and AKT-dependent process Oncogene, 2004, 23, 1364-1376.
123. Mukhopadhyay, I.; Sausville, E. A.; Doroshow, J. H.; Roy, K. K. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways, J. Biol. Chem., 2006, 281, 37330-37344.
124. Zini, R.; Morin, C.; Bertelli, A.; Bertelli, A. A.; Tillement, J. P. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp. Clin. Res., 1999, 25, 87-97.
125. Tinhofer, I.; Bernhard, D.; Senfter, M.; Anether, G.; Loeffler, M.; Kroemer, G.; Kofler, R.; Csordas, A.; Greil, R. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J., 2001, 15, 1613-1615.
126. Athar, M.; Back, J. H.; Tang, X.; Kim, K. H.; Kopelovich, L.; Bickers, D. R.; Kim, A. L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol., 2007, 224, 274-283.
127. Harikumar, K. B.; Aggarwal, B. B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle, 2008, 7, 1020-1035.
128. Strathmann, J.; Klimo, K.; Sauer, S. W.; Okun, J. G.; Prehn, J. H.; Gerhauser, C. Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondria-mediated mechanism. FASEB J., 2010.
129. Colgate, E. C.; Miranda, C. L.; Stevens, J. F.; Bray, T. M.; Ho, E. Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett., 2007, 246, 201-209.
130. Albini, A.; Dell'Eva, R.; Vene, R.; Ferrari, N.; Buhler, D. R.; Noonan, D. M.; Fassina, G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J., 2006, 20, 527-529.
131. Lust, S.; Vanhoecke, B. M. V. A. N. G.; Boelens, J. H.V. A. N. M.; Kaileh, M.; Vanden Berghe, W.; Haegeman, G.; Philippe, J.; Bracke, M.; Offner, F. Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia. Anticancer Res., 2009, 29, 3797-3805.
132. Harikumar, K. B.; Kunnumakkara, A. B.; Ahn, K. S.; Anand, P.; Krishnan, S.; Guha, S.; Aggarwal, B. B. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood, 2009, 113, 2003-2013.
133. Monteiro, R.; Calhau, C.; Silva, A. O.; Pinheiro-Silva, S.; Guerreiro, S.; Gartner, F.; Azevedo, I.; Soares, R. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J. Cell Biochem., 2008, 104, 1699-1707.
134. Miranda, C. L.; Stevens, J. F.; Helmrich, A.; Henderson, M. C.; Rodriguez, R. J.; Yang, Y. H.; Deinzer, M. L.; Barnes, D. W.; Buhler, D. R. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem. Toxicol., 1999, 37, 271-285.
135. Xiao, D.; Powolny, A. A.; Singh, S. V. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J. Biol. Chem., 2008, 283, 30151-30163.
136. Sahu, R. P.; Zhang, R.; Batra, S.; Shi, Y.; Srivastava, S. K. Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis, 2009, 30, 1744-1753.
137. Nakamura, Y.; Kawakami, M.; Yoshihiro, A.; Miyoshi, N.; Ohigashi, H.; Kawai, K.; Osawa, T.; Uchida, K. Involvement of the mitochondrial death pathway in chemopreventive benzyl isothiocyanate-induced apoptosis. J. Biol. Chem., 2002, 277, 8492-8499.
138. Warin, R.; Xiao, D.; Arlotti, J. A.; Bommareddy, A.; Singh, S. V. Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate. Mol. Carcinog, 2010, 49, 500-507.
139. Yang, Y. M.; Conaway, C. C.; Chiao, J. W.; Wang, C. X.; Amin, S.; Whysner, J.; Dai, W.; Reinhardt, J.; Chung, F. L. Inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res., 2002, 62, 2-7.
140. Warin, R.; Chambers, W. H.; Potter, D. M.; Singh, S. V. Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res., 2009, 69, 9473-9480.
141. Trachootham, D.; Zhou, Y.; Zhang, H.; Demizu, Y.; Chen, Z.; Pelicano, H.; Chiao, P. J.; Achanta, G.; Arlinghaus, R. B.; Liu, J.; Huang, P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 2006, 10, 241-252.
142. Brown, K. K.; Cox, A. G.; Hampton, M. B. Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS Lett., 2010, 584, 1257-1262.
143. Facompre, M.; Tardy, C.; Bal-Mahieu, C.; Colson, P.; Perez, C.; Manzanares, I.; Cuevas, C.; Bailly, C. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res., 2003, 63, 7392-7399.
144. Davis, R. A.; Carroll, A. R.; Pierens, G. K.; Quinn, R. J. New lamellarin alkaloids from the australian ascidian, didemnum chartaceum. J. Nat. Prod., 1999, 62, 419-424.
145. Kluza, J.; Gallego, M. A.; Loyens, A.; Beauvillain, J. C.; Sousa-Faro, J. M.; Cuevas, C.; Marchetti, P.; Bailly, C. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res., 2006, 66, 3177-3187.
146. Ballot, C.; Kluza, J.; Martoriati, A.; Nyman, U.; Formstecher, P.; Joseph, B.; Bailly, C.; Marchetti, P. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D. Mol. Cancer Ther., 2009, 8, 3307-3317.
147. Ballot, C.; Kluza, J.; Lancel, S.; Martoriati, A.; Hassoun, S. M.; Mortier, L.; Vienne, J. C.; Briand, G.; Formstecher, P.; Bailly, C.; Neviere, R.; Marchetti, P. Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis, 2010, 15, 769-781.
148. Gallego, M. A.; Ballot, C.; Kluza, J.; Hajji, N.; Martoriati, A.; Castera, L.; Cuevas, C.; Formstecher, P.; Joseph, B.; Kroemer, G.; Bailly, C.; Marchetti, P. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene, 2008, 27, 1981-1992.
149. Fukuda, R.; Zhang, H.; Kim, J. W.; Shimoda, L.; Dang, C. V.; Semenza, G. L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell, 2007, 129, 111-122.
150. Moncada, S.; Erusalimsky, J. D. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat. Rev. Mol. Cell Biol., 2002, 3, 214-220.
151. Slapke, J.; Schewe, T.; Hummel, S.; Winkler, J.; Kopf, M. Lung strips from guinea pigs as test system for lipoxygenase inhibitors. Inhibition of arachidonic acid-induced contractions by 3-t-butyl-4-hydroxyanisole and nordihydroguaiaretic acid. Biomed. Biochim. Acta, 1983, 42, 1309-1318.
152. Okubo, T.; Yokoyama, Y.; Kano, K.; Kano, I. Molecular mechanism of cell death induced by the antioxidant tertbutylhydroxyanisole in human monocytic leukemia U937 cells. Biol. Pharm. Bull, 2004, 27, 295-302.
153. Festjens, N.; Kalai, M.; Smet, J.; Meeus, A.; Van Coster, R.; Saelens, X.; Vandenabeele, P. Butylated hydroxyanisole is more than a reactive oxygen species scavenger. Cell Death Differ., 2006, 13, 166-169.
154. Shaban, H.; Gazzotti, P.; Richter, C. Cytochrome c oxidase inhibition by N-retinyl-N-retinylidene ethanolamine, a compound suspected to cause age-related macula degeneration. Arch Biochem. Biophys., 2001, 394, 111-116.
155. Suter, M.; Reme, C.; Grimm, C.; Wenzel, A.; Jaattela, M.; Esser, P.; Kociok, N.; Leist, M.; Richter, C. Age-related macular degeneration. The lipofusion component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J. Biol. Chem., 2000, 275, 39625-39630.
156. Hilf, R. Mitochondria are targets of photodynamic therapy. J. Bioenerg Biomembr., 2007, 39, 85-9.
157. You, K. R.; Wen, J.; Lee, S. T.; Kim, D. G. Cytochrome c oxidase subunit III: a molecular marker for N-(4-hydroxyphenyl) retinamise-induced oxidative stress in hepatoma cells. J. Biol. Chem., 2002, 277, 3870-3877.
158. Chandran, K.; Aggarwal, D.; Migrino, R. Q.; Joseph, J.; McAllister, D.; Konorev, E. A.; Antholine, W. E.; Zielonka, J.; Srinivasan, S.; Avadhani, N. G.; Kalyanaraman, B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys. J., 2009, 96, 1388-1398.
159. Papadopoulou, L. C.; Tsiftsoglou, A. S. Mitochondrial cytochrome c oxidase as a target site for daunomycin in K-562 cells and heart tissue. Cancer Res., 1993, 53, 1072-1078.
160. Devenish, R. J.; Prescott, M.; Rodgers, A. J. The structure and function of mitochondrial F1F0-ATP synthases. Int. Rev. Cell Mol. Biol., 2008, 267, 1-58.
161. Junge, W.; Sielaff, H.; Engelbrecht, S. Torque generation and elastic power transmission in the rotary F(O)F(1)-ATPase. Nature, 2009, 459, 364-370.
162. Salomon, A. R.; Voehringer, D. W.; Herzenberg, L. A.; Khosla, C. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem. Biol., 2001, 8, 71-80.
163. Salomon, A. R.; Voehringer, D. W.; Herzenberg, L. A.; Khosla, C. Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase. Proc. Natl. Acad Sci. USA, 2000, 97, 14766-14771.
164. Liu, X.; Luo, X.; Shi, Y.; Zhu, G. D.; Penning, T.; Giranda, V. L.; Luo, Y. Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol. Ther., 2008, 7, 934-941.
165. Zamaraeva, M. V.; Sabirov, R. Z.; Maeno, E.; Ando-Akatsuka, Y.; Bessonova, S. V.; Okada, Y. Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase. Cell Death Differ., 2005, 12, 1390-1397.
166. Eguchi, Y.; Shimizu, S.; Tsujimoto, Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res., 1997, 57, 1835-1840.
167. Leist, M.; Single, B.; Castoldi, A. F.; Kuhnle, S.; Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med., 1997, 185, 1481-1486.
168. Matsuyama, S.; Llopis, J.; Deveraux, Q. L.; Tsien, R. Y.; Reed, J. C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell Biol., 2000, 2, 318-325.
169. Zheng, J.; Ramirez, V. D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol., 2000, 130, 1115-1123.
170. Gledhill, J. R.; Montgomery, M. G.; Leslie, A. G.; Walker, J. E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad Sci. USA, 2007, 104, 13632-13637.
171. Gong, Y.; Sohn, H.; Xue, L.; Firestone, G. L.; Bjeldanes, L. F. 3,3'-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res., 2006, 66, 4880-4887.
172. Safe, S.; Papineni, S.; Chintharlapalli, S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett., 2008, 269, 326-338.
173. Reed, G. A.; Sunega, J. M.; Sullivan, D. K.; Gray, J. C.; Mayo, M. S.; Crowell, J. A.; Hurwitz, A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 2619-24.
174. Wiatrak, B. J. Overview of recurrent respiratory papillomatosis. Curr. Opin. Otolaryngol. Head Neck Surg., 2003, 11, 433-441.
175. Johnson, K. M.; Cleary, J.; Fierke, C. A.; Opipari, A. W., Jr.; Glick, G. D. Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase. ACS Chem. Biol., 2006, 1, 304-308.
176. Johnson, K. M.; Chen, X.; Boitano, A.; Swenson, L.; Opipari, A. W., Jr.; Glick, G. D. Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423. Chem. Biol., 2005, 12, 485-496.
177. Boitano, A.; Ellman, J. A.; Glick, G. D.; Opipari, A. W. Jr. The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells. Cancer Res., 2003, 63, 6870-6876.
178. Blatt, N. B.; Boitano, A. E.; Lyssiotis, C. A.; Opipari, A. W., Jr.; Glick, G. D. Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax. Free Radic. Biol. Med., 2008, 45, 1232-1242.
179. Bullough, D. A.; Ceccarelli, E. A.; Roise, D.; Allison, W. S. Inhibition of the bovine-heart mitochondrial F1-ATPase by cationic dyes and amphipathic peptides. Biochim. Biophys. Acta, 1989, 975, 377-383.
180. Bernal, S. D.; Lampidis, T. J.; McIsaac, R. M.; Chen, L. B. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrialspecific dye. Science, 1983, 222, 169-172.
181. Bernal, S. D.; Lampidis, T. J.; Summerhayes, I. C.; Chen, L. B. Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science, 1982, 218, 1117-1119.
182. Herr, H. W.; Huffman, J. L.; Huryk, R.; Heston, W. D.; Melamed, M. R.; Whitmore, W. F. Jr. Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma, Cancer Res., 1988, 48, 2061-2063.
183. Jones, L. W.; Narayan, K. S.; Shapiro, C. E.; Sweatman, T. W. Rhodamine-123: therapy for hormone refractory prostate cancer, a phase I clinical trial. J. Chemother., 2005, 17, 435-440.
184. Britten, C. D.; Rowinsky, E. K.; Baker, S. D.; Weiss, G. R.; Smith, L.; Stephenson, J.; Rothenberg, M.; Smetzer, L.; Cramer, J.; Collins, W.; Von Hoff, D. D.; Eckhardt, S. G. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin. Cancer Res., 2000, 6, 42-49.
185. Propper, D. J.; Braybrooke, J. P.; Taylor, D. J.; Lodi, R.; Styles, P.; Cramer, J. A.; Collins, W. C.; Levitt, N. C.; Talbot, D. C.; Ganesan, T. S.; Harris, A. L. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann. Oncol., 1999, 10, 923-927.
186. Gottlieb, E.; Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer, 2005, 5, 857-866.
187. Fath, M. A.; Diers, A. R.; Aykin-Burns, N.; Simons, A. L.; Hua, L.; Spitz, D. R. Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol. Ther., 2009, 8, 1228-1236.